NewLimit moves its lead liver prototypes to clinical-grade lipid chemistry as the first step toward a human trial

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit began moving its most advanced liver prototypes from chemistry suited to animal work toward clinical-grade formulations, taking the first step toward human trials expected within the coming years.

• Transition from animal-suitable lipid and RNA chemistry to higher-quality formulations required for human trials.
• Clinical-grade chemistry upgrade enables regulatory pathway and manufacturing scale-up for human studies.
• Human trials expected within several years following chemistry and manufacturing optimization.